Edesa Biotech: FDA clears IND for Phase 2 vitiligo study

What happened Edesa Biotech reported on Oct 15, 2026 that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling the company to expand recruitment to the United States. Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter. The company anticipates that topline data will be available fourth quarter 2027.

Key details

• The study is a double-blind, placebo-controlled clinical trial evaluating EB06 in up to 80 adults with moderate-to-severe nonsegmental vitiligo; participants are randomized 1:1 to receive EB06 or placebo every two weeks through Week 22.
• The primary efficacy endpoint is the mean percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Week 28.
• Secondary and exploratory measures include facial and total-body scoring benchmarks, and assessments of safety, tolerability, pharmacokinetics and immunogenicity.
• EB06 is described as a fully human monoclonal antibody targeting CXCL10, intended to inhibit CXCL10 and interrupt immune-cell recruitment and melanocyte loss.

Why it may matter This report was made under Item 8.01: Other events, which covers other corporate or regulatory developments. The filing states that the FDA cleared the IND for the Phase 2 study of EB06 and that safety and efficacy remain subject to clinical evaluation. This filing does not show why the insider traded or why the company acted.